No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Elanco Animal Health, Inc. develops, manufactures, and markets products for pets and farm animals. Its products include Advantage Family, Atopica, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, TruCan, AviPro, Baytril, Catosal, Denagard, and Experior. The company was founded in 1954 and is headquartered in Indianapolis, IN.
www.elanco.comNo one on the platform currently holds 5EA.DE.
No tracked institution reports a position in 5EA.DE as of their last filing.
No one on the platform has traded 5EA.DE yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | 6.2% | 7.6% | ||||
| Profit Margin % | -4.9% | -7.4% | -6.2% | |||
| Free Cash Flow Margin % | 6.0% | 6.5% | 4.6% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $5.1B | +8.4% | $1.12 | $1.10–$1.13 | — | 1 |
| 2027 | $5.3B | +5.4% | $1.25 | $1.24–$1.26 | — | 1 |
| 2028 | $5.6B | +5.0% | $1.43 | $1.41–$1.44 | — | 1 |
| 2029 | $5.9B | +5.0% | $1.56 | $1.54–$1.58 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-05 | $0.24 | $0.30 | +26.3% |
| 2026-05-07 | $0.30 | $0.35 | +15.7% |
| 2026-02-24 | $0.10 | $0.11 | +14.6% |
| 2025-11-05 | $0.11 | $0.16 | +46.1% |
| 2025-08-07 | $0.17 | $0.22 | +30.8% |
| 2025-05-07 | $0.28 | $0.34 | +20.8% |
| 2025-02-25 | $0.14 | $0.14 | -6.0% |
| 2024-11-07 | $0.11 |
| $0.12 |
| +6.3% |
| +0.13% |
| $3.2B |
| — |
| ILU.DEIllumina, Inc. | $124.28 | +0.60% | $18.8B | — |
| NP5.DENewron Pharmaceuticals S.p.A. | $11.35 | -2.99% | $236M | — |
Source: Financial Modeling Prep · peers by sector/industry